Background-Hyperhomocysteinemia is a risk factor for cardiovascular disease. Coactivator-associated arginine methyltransferase 1 (CARM1) participates in the synthesis of homocysteine, but whether the genetic variations regulate CARM1 expression and homocysteine levels remains unknown. Methods and Results-Functional analyses combined with an association study were conducted to identify the causal variant for CARM1 expression and homocysteine levels. Based on functional annotations obtained from Encyclopedia of DNA Elements, we selected 4 potentially functional single-nucleotide polymorphisms in the CARM1 gene and investigated their effect on CARM1 transcription levels in vivo. rs117569851, located in the promoter region of CARM1, as well as rs12460421 and rs4804544, was associated with CARM1 expression levels, and the last 2 single-nucleotide polymorphisms were discovered in high linkage disequilibrium with rs117569851 (r 2 =0.9 and 1.0) in our study sample. rs117569851 was further identified to be responsible for regulating CARM1 expression. The T allele disrupted the binding of early growth response-1, which led to the downregulation of transcriptional activity in vitro and CARM1 mRNA levels in vivo. In addition, rs117569851 was associated with plasma homocysteine levels in a Chinese population (n=406), with a 2.16 μmol/L decrease per copy of T allele. Conclusions-The present study suggests that a noncoding variant in the CARM1-promoter functions as a regulator of gene transcription and homocysteine levels. (Circ Cardiovasc Genet. 2014;7:642-649.)
H omocysteine is a well-known atherogenic factor illustrated by extensive evidence. McCully 1-3 first reported the presence of atherosclerosis in patients with deficiencies in homocysteine metabolic enzymes and in animal models with homocysteine administration. Furthermore, several basic researches have revealed the mechanisms of homocysteine in the pathogenesis of atherosclerosis, including endothelial cell cytotoxicity, 4, 5 vascular smooth muscle cell proliferation, 6 and oxidation of low-density lipoproteins. 7 Moreover, observational studies have shown that elevated homocysteine is related to a higher risk of vascular disease such as coronary heart disease, [8] [9] [10] [11] [12] peripheral vascular disease, 13 and stroke. [14] [15] [16] 
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Because most homocysteine-lowering trials failed to demonstrate any benefit in patients with atherosclerosis, 17, 18 it is essential to clarify the genetic background of homocysteine metabolism in the general population. Homocysteine is an intermediate in methionine metabolism, which is generated from the transmethylation of methionine and degraded via transsulphuration to cysteine or remethylation back to methionine (Figure 1 ). Several single-nucleotide polymorphisms (SNPs) of the key enzymes in homocysteine degradation pathways have been identified to be associated with mild to moderate elevations in homocysteine levels or with vascular disease risks, such as methylenetetrahydrofolate reductase, [19] [20] [21] [22] 5-methyltetrahydrofolate-homocysteine methyltransferase, 21 and cystathionine βsynthase. 23, 24 However, they only explain 4% to 9% of the variance in plasma homocysteine levels. 25 Therefore, it is essential to determine other candidate genes that regulate homocysteine metabolism.
Coactivator-associated arginine methyltransferase 1 (CARM1) is involved in the synthesis of homocysteine. It catalyzes the transfer of a methyl group from S-adenosylmethionine to generate S-adenosylhomocysteine, the precursor of homocysteine. Kullo et al 26 reported that CARM1 is present under the significant linkage signals for homocysteine in 1319 black sibships. However, they did not identify the risk locus in CARM1 for elevated homocysteine.
In the present study, we assessed the effect of 4 potentially functional SNPs on CARM1 transcription in vivo and further identified the functional variant for regulating CARM1 expression by functional analyses. Finally, we confirmed the association between the functional variant and plasma homocysteine levels in a Han Chinese population.
Methods

Study Subjects
All study protocols were approved by the institutional review ethics boards of Fuwai Hospital, the Chinese Academy of Medical Sciences, and Peking Union Medical College. The protocols were in compliance with the Declaration of Helsinki, and written informed consent was obtained from each subject before the commencement of the study.
Two independent cohorts of adults aged 30 to 60 years were studied (Table) . Cohort 1, consisting of 194 subjects (81 men, 113 women) from rural district of Shandong Province, was enrolled in the China Cardiovascular Health Study project, a population-based investigation of risk factors for cardiovascular diseases in China since 2006. 27 In general, individuals were excluded from the study if they had stage II/III hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg); a history of coronary heart disease, diabetes mellitus, stroke, or renal or hepatic disease; or took antihypertensive medications in the past 2 weeks. Peripheral blood mononuclear cells (PBMCs) were isolated from their fresh peripheral blood for transcription assays of the CARM1 gene. Details on the isolation of PBMCs are described in the expanded methods section available in the Data Supplement.
For homocysteine association study, cohort 2 comprised 406 healthy individuals participating in the Epidemiological Survey of Major Non-Communicable Chronic Diseases and their Risk Factors in Beijing. Trained interviewers administered a standard questionnaire to collect information on demographic characteristics, including age, sex, ethnicity, smoking, alcohol consumption (yes if drinking ≤12 times in the last 12 months, and no if less), and medical history. Blood pressure, height, and weight were also measured by a trained staff member.
RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from isolated PBMCs with conventional reagents and reverse-transcribed using TransScript First-Strand cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China) with oligo (dT) 15 primers. CARM1 mRNA (RefSeq NM_199141.1) levels were measured by quantitative real-time polymerase chain reaction (PCR) with the ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The reaction mixture contained 0.2 μmol/L of each primer, 2× select SYBR master mix (ABI), and 1 μL complementary DNA (1:8 dilution). The PCR amplification was performed as follows: 50°C for 2 minutes, 95°C for 2 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Relative quantification was performed using the ∆∆Ct method, and fold changes were calculated. 28 GAPDH (RefSeq NM_002046.4) was selected as an endogenous control. Amplifications were performed in triplicate for each sample. The primers used are listed in Table I in the Data Supplement.
DNA Extraction and Genotyping
Genomic DNA was isolated from peripheral venous blood using a commercial DNA extraction kit (Tiangen Biotech, Beijing, China). Genotyping for rs12460421, rs117569851, rs4804544, and rs12977506 was performed using a TaqMan genotyping platform (ABI 7900HT Real Time PCR system; Applied Biosystems). The primers and probes are shown in Table I in the Data Supplement. The thermocycler parameters were as follows: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. The successful genotyping rate was >98%, and 2% of the samples were randomly selected and genotyped in duplicate. The discrepancy between them was <1%.
Plasmid Constructs
To construct the CARM1-promoter reporter plasmid, a 1363-bp genomic fragment encompassing −1221 to +141 bp of the human CARM1-promoter was amplified by PCR from human genomic DNA with rs12460421 to rs117569851 haplotype A-T. The PCR product was subcloned into the KpnI and XhoI sites of the pGL3-basic vector (Promega, Madison, WI) upstream of the reporter gene. The haplotype G-T and G-C plasmid constructs were generated by site-directed mutagenesis. All constructs were verified by DNA sequencing. The primers are listed in Table I in the Data Supplement.
Cell Culture, Transfection, and Luciferase Assays
Human embryonic kidney 293T (HEK293T) cells and human colorectal cancer HT-29 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% FBS (Hyclone, Logan, UT) at 37°C in a humidified incubator containing 5% CO 2 . About 1.5×10 5 HEK293T cells were seeded in 24-well culture plates and transfected at roughly 70% confluence in triplicate. About 1.2 μg of firefly luciferase reporter constructs were cotransfected with 0.1 μg renilla luciferase pRL-TK vector (Promega) as an internal control using 0.5 μL Vigorous transfection reagent (Vigorous Biotechnology, Beijing, China) in each well. After 24 hours, the Continuous variables are mean±SD. BMI indicates body mass index; DBP, diastolic blood pressure; Hcy, homocysteine; ND, no data; and SBP, systolic blood pressure. transfected cells were lysed in passive lysis buffer and luciferase activities were measured with the Dual-Luciferase Reporter Activity Assay System (Promega) according to the manufacturer's protocol. Four independent transfection experiments were performed, and each luciferase assay was performed in triplicate.
Electrophoretic Mobility Shift Assay
Details of the electrophoretic mobility shift assay (EMSA) performed in this study are provided in the Data Supplement. In brief, probes for rs117569851 were designed based on genomic sequences surrounding the SNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), and probes with the early growth response-1 (Egr-1) consensus binding site were described previously. 29 The sequences of each probe are listed in Table I in the Data Supplement. Gel shift assays were performed using the LightShift Chemiluminescent EMSA Kit (Thermo Scientific Pierce, Waltham, MA) according to the manufacturer's instructions. For competition assays, 100-fold excesses of unlabeled probes were preincubated with nuclear extract before the addition of the labeled probe. For multiplexed competitor EMSA, as described by Smith et al, 30 excess unlabeled competitor probes containing consensus sequences for well-characterized transcription factors were multiplexed and divided into 7 groups. Each group of mixed DNA competitors (2.5 pmol of each competitor) to specific transcription factors was preincubated with nuclear extract at 25°C for 5 minutes. The labeled DNA probe (25 fmol) was then added into each group and incubated at 4°C for 15 minutes and at 25°C for 10 minutes. The competitor probe of the functional transcription factor produced elimination of the band for a particular set of transcription factors. For supershift assays, HEK293T nuclear extract was preincubated with the antibody against Egr-1 (sc-189×; Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes at 4°C.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed with the EZ ChIP Kit (Upstate, Lake Placid, NY). Details are described in the Data Supplement. Briefly, crosslinked cells were sonicated and immunoprecipitated with antibodies against Egr-1 or nonspecific rabbit IgG (Santa Cruz Biotechnology) overnight at 4°C. The enrichment of immunoprecipitated DNA was assessed by PCR and gel electrophoresis. Allele-specific binding of Egr-1 to the rs117569851containing site was measured by quantitative real-time PCR with TaqMan probes corresponding to the surrounding sequence of rs117569851 (C probe: VIC-CCGACGCACCCTC; T probe: FAM-CCCGAC GTACCCTC). The amplified 121 bp region was encompassing −346 to −226 bp of the human CARM1-promoter. The primers are listed in Table I 
Measurement of Homocysteine
Peripheral venous blood was obtained from fasting subjects and immediately centrifuged and frozen at −80°C. The total plasma homocysteine level was determined by enzyme immunoassay. This method has been demonstrated to be highly correlated with both high-performance liquid chromatography and gas chromatography-mass spectrometry methods. 31
Statistical Analysis
All statistical analyses were performed with SPSS 15.0 software (SPSS, Chicago, IL). The normality assumption of data distribution was tested using the Shapiro-Wilk test. Differences in categorical variables and Hardy−Weinberg equilibrium were tested by a χ 2 test. Comparisons of continuous variables were analyzed by an unpaired t test and ANOVA, as appropriate. Because data of luciferase activity and ratios of T allele/C allele from ChIP were not normally distributed, nonparametric Mann-Whitney U test was used to compare differences between 2 groups. The association between the number of minor alleles and plasma homocysteine levels was tested by general linear regression under an additive genetic model with or without adjustment for age, sex, body mass index, smoking, and drinking status. The effect sizes (β and SE) per copy of minor allele were also estimated. The study had 80% power to detect a β of 2.0 μmol/L per allele copy for rs117569851 with a minor allele frequency of 0.4 (estimated by Quanto; http://hydra.usc.edu/gxe/). All statistical tests were 2-tailed, and P<0.05 was considered significant. Linkage disequilibrium analysis was performed using Haploview version 4.2. 32
Results
Prediction of Potentially Functional SNPs in the CARM1 Gene
We first reviewed SNPs in the range 10 kb 5′ to 10 kb 3′ of the CARM1 gene in a Han Chinese population enrolled in the HapMap Project (version 3, release 27) by Haploview version 4.2. There were 19 SNPs with a minor allele frequency ≥0.01.
A strategy searching for functionality was to use annotations of gene regulatory regions from Encyclopedia of DNA Elements (http://genome.ucsc.edu/ENCODE/; Figure 2 ; Table II in the Data Supplement). Because promoter region is important for gene expression, we also reviewed SNPs in the promoter of CARM1 from the 1000 Genome Project. Because promoters of genes are associated with histone H3 trimethylated at lysine4 (H3K4me3), rs12460421 and rs117569851 were predicted in the promoter region of CARM1 by looking for this mark and were selected for further study. Marks indicative of enhancers include the enrichment of histone H3 monomethylation at lysine 4 (H3K4me1), histone H3 acetylation at lysine27 (H3Ac27), and the presence of DNase І hypersensitivity clusters and binding sites of transcription factors. 33 Looking for enhancer marks, we preferentially selected rs12977506 and rs4804544 for further study.
Effect of Potentially Functional SNPs on CARM1 mRNA Levels In Vivo
To determine whether potentially functional SNPs affected CARM1 gene transcription in vivo, we compared the mRNA levels of CARM1 in PBMCs from 194 individuals among 3 genotypes of each SNP. The linkage disequilibrium analyses from this study population showed that rs117569851 was in a complete linkage disequilibrium with rs4804544 (r 2 =1) and in a high linkage disequilibrium with rs12460421 (r 2 =0.90; Figure 3A ). Genotype frequencies of 4 tested SNPs were in accordance with the Hardy-Weinberg expectation (rs12460421, P=0.72; rs117569851, P=0.75; rs12977506, P=0.95; rs4804544, P=0.75). rs12460421, rs117569851, and rs4804544 were significantly correlated with CARM1 expression ( Figure 3B and 3C) . However, rs12977506 appeared to have no effect on CARM1 mRNA levels in this study ( Figure 3D ). The AA homozygotes of rs12460421 had lower levels of CARM1 transcript than the GG homozygotes (AA versus GG: 0.71±0.05 versus 0.99±0.10), and carriers with 1 copy of the T allele of rs117569851 or the A allele of rs4804544 also had a 23% reduction in the CARM1 expression compared with noncarriers (0.79±0.05 versus 1.03±0.11).
Allele-Specific Effect of rs117569851 on Transcriptional Activity In Vitro
Because rs12460421 and rs117569851 were predicted in the CARM1-promoter, we preferentially confirmed the allele-specific effects of both of them on transcriptional activity. The renilla luciferase-expressing plasmids into HEK293T cells. As expected, the 3 CARM1-promoter constructs had higher promoter activities than the empty vector. The construct containing the T allele of rs117569851 had a significant 55% lower reporter gene expression than that containing the C allele ( Figure 4B) , which was consistent with CARM1 expression pattern in PBMCs. However, the A allele of rs12460421 slightly increased the reporter activity, which was not in accordance with the CARM1 expression pattern in vivo. These results indicated that rs117569851 was more likely to be the functional variant for regulating CARM1 expression.
rs117569851 Attenuates Transcription Factor Egr-1-Binding Affinity
Functional SNPs in the promoter region usually affect gene expression via specific binding to transcription factors. Thus, we performed EMSA to examine the binding pattern of nuclear proteins on the site of rs117569851. As shown in Figure 5A , the binding patterns of rs117569851 alleles were different from each other. When equal amounts of biotin-labeled probes were incubated with nuclear proteins from HEK293T cells, the rs117569851 C probe formed more DNA-protein complexes in band 1 and fewer complexes in bands 2 and 3 ( Figure 5A , lane 2) than the T probe ( Figure 5A, lane 5) . Competition assays indicated that additional unlabeled probe completely disturbed the DNA-protein complex formation ( Figure 5A, lanes 3 and 6) .
To identify the transcription factors binding to rs117569851, multiplexed competitor EMSA was conducted as described in the Methods section. The result showed that the second group of multiplexed competitors remarkably eliminated the shifted bands formed by the interaction between the C probe of rs117569851 and nuclear proteins ( Figure 5B, lane 4) . A further EMSA using individual competitors from the second group indicated that bands 2 and 3 were formed because of the binding of Egr-1 to the C probe of rs117569851 ( Figure 5C ). Moreover, the C probe of rs117569851 preincubated with Egr-1 antibodies produced the same supershift as the probe containing the Egr-1 consensus sequence ( Figure 5D ), confirming the specificity of Egr-1-DNA binding.
Furthermore, we performed ChIP assays to determine the level of the binding of Egr-1 to the site of rs117569851 in intact cells. The putative binding site for Egr-1 on the CARM1-promoter was illustrated in Figure 6A . We genotyped for rs117569851 in 25 different cell lines to determine the heterozygote (see Table III in the Data Supplement). The ChIP conducted in heterozygous HT29 cells showed that the rs117569851-containing region was occupied by the transcription factor Egr-1 ( Figure 6B) , and the T allele of rs117569851 had lower binding affinity for Egr-1 than the C allele ( Figure 6C ). Taken together, these results demonstrate that rs117569851 in the CARM1-promoter is within the Egr-1-binding site, and the T-to-C substitution results in a different binding affinity for Egr-1.
Association of rs117569851 with Plasma Homocysteine Levels
To examine whether the functional variant rs117569851 is associated with homocysteine levels, we genotyped for this SNP and detected plasma homocysteine concentrations in a Chinese Han population of 406 healthy individuals. The T allele frequency was 0.422, and the genotype frequencies were in accordance with the Hardy-Weinberg expectation in this population (P=0.366). The analyses under an additive genetic model showed that rs117569851 was significantly associated with decreased levels of plasma homocysteine (Figure 7) , both with or without adjustment for risk factors affecting homocysteine levels, including age, sex, body mass index, smoking, 
Discussion
The present study showed that rs117569851 regulates CARM1 expression and plasma homocysteine levels. The functional analysis showed that the variant affected the activity of CARM1-promoter in an allele-dependent manner leading to decreased levels of CARM1 expression in PBMCs. The mechanism of its effect on transcription involved the disruption of Egr-1 transcription factor-binding site. Moreover, rs117569851 was associated with reduced plasma homocysteine levels in a Chinese population. Together, these findings suggest that rs117569851 is functionally responsible for the association of CARM1 with its expression and circulating levels of homocysteine.
Our data confirmed the role of CARM1 in regulating homocysteine metabolism. rs117569851, in the promoter of CARM1, was associated with plasma homocysteine levels in a Chinese population, specifically urbanites in the north of China with above-normal mean level of homocysteine. Regardless of different races of the sample groups between our study and that of Kullo et al, 26 the consistent results strongly imply that CARM1 contributes to the regulation of homocysteine. However, our result did not overlap with the 2 genomewide linkage studies in Europeans that identified nicotinamide N-methyltransferase and ras-related nuclear protein as genetic determinants of plasma homocysteine levels. 26, 34 Higher folate intake in Europeans than in Chinese is likely one of the reasons interpretating the inconsistency between Europeans and Chinese. Elevated activity of intracellular methyltransferases is associated with increased cellular homocysteine. 35 Moreover, mice deficient in phosphatidyl-ethanolamine N-methyltransferase have reduced plasma homocysteine levels and attenuated atherosclerosis. 36, 37 These lines of evidence suggest that the S-adenosyl-L-methionine-dependent methyltranferases play an important role in regulating plasma homocysteine and, consequently, in atherosclerosis.
We further identified rs117569851 as the functional variant for regulating CARM1 expression and homocysteine levels. The functional analysis showed that the T allele of rs117569851 significantly reduced the transcriptional activity by the detection of in vivo CARM1 expression levels and in vitro luciferase reporter activity. The EMSA and ChIP data suggested that the T allele of rs117569851 attenuated the binding affinity for Egr-1. Moreover, the association study indicated that carriers of the T allele of rs117569851 had decreased levels of plasma homocysteine. In contrast, rs12460421 was unlikely a functional variant for CARM1 expression. We found the A allele of rs12460421 displayed a higher binding affinity for Egr-1 leading to slightly increased transcriptional activity (see Figures II and III in the Data Supplement). However, individuals homozygous for the A allele of rs12460421 had reduced expression of CARM1, which indicated that rs12460421 might be a functional variant regulating other target gene transcription and not CARM1.
To the best of our knowledge, this is the first time that Egr-1 regulation of CARM1 expression through binding the CARM1-promoter region has been reported. Egr-1, a C2H2type zinc-finger transcription factor, modulates target genes involving cell differentiation, mitogenesis, and stress response. According to previous studies, Egr-1 plays a pivotal role in the progression of atherosclerosis. [38] [39] [40] Experimental evidence suggested that Egr-1 transcripts are upregulated in human atherosclerotic plaques versus adjacent unaffected tissue. 38 Furthermore, mice deficient in Egr-1 displayed decreased atherosclerosis and vascular inflammation. 40 Thus, CARM1 targeted by Egr-1 might play a role in the pathogenesis of atherosclerosis. This hypothesis will be verified in further studies with an illustration of the molecular mechanism.
A limitation of the present study is that dietary habits, which may influence plasma homocysteine levels, were not accounted for.
In conclusion, our study suggests that a novel functional polymorphism in the CARM1-promoter is responsible for reduced CARM1 expression and plasma homocysteine levels by affecting transcriptional activity owing to attenuated binding to the Egr-1 transcription factor. This may lead to a better understanding of the genetic variants when determining plasma homocysteine levels.
